Search
Cosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalOn December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Dihydro-alpha-ergocryptine
go.drugbank.com/drugs/DB11274ApprovedAlpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049] … These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine.
Capra hircus hair
go.drugbank.com/drugs/DB10876ApprovedDomestic goat hair is used in allergenic testing.
Mixtures: Treatment Set TS330316, Treatment Set TS330170Deramciclane
go.drugbank.com/drugs/DB06512InvestigationalDeramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target. … It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.
Testosterone undecanoate
go.drugbank.com/drugs/DB13946ApprovedInvestigational[L35970] It was developed via fatty acid esterification of testosterone in order to achieve orally administer testosterone. … Testosterone undecanoate is the ester prodrug of [testosterone] and has a mid-chain fatty acid at the carbon 17β position.
Products: Andriol Testocaps 40 mg - Kapseln, Nebido 1000 mg/4 ml InjektionslösungLiquidambar styraciflua pollen
go.drugbank.com/drugs/DB10495ApprovedLiquidambar styraciflua pollen is mainly used in allergenic testing.
Mixtures: Treatment Set TS333938, Treatment Set TS128872Safrazine
go.drugbank.com/drugs/DB09253ApprovedWithdrawnIn 1960, it was used as an antidepressant but it is now discontinued.
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. … [A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018.
Products: XOSPATA 40 MG FİLM KAPLI TABLET, 84 ADETSuvorexant
go.drugbank.com/drugs/DB09034ApprovedInvestigationalIt has been approved for the treatment of insomnia.
Products: BELSOMRA® 15 MG, BELSOMRA® 10 MGIron Dextran
go.drugbank.com/drugs/DB00893ApprovedInvestigationalVet approvedIron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible.
Categories: Compounds used in a research, industrial, or household setting